Literature DB >> 26676577

Adopting ALK and LTK.

Greg Lemke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26676577      PMCID： PMC4702950          DOI： 10.1073/pnas.1521923113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  16 in total

Review 1.  Cellular signaling by fibroblast growth factor receptors.

Authors:  V P Eswarakumar; I Lax; J Schlessinger
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-01       Impact factor: 7.638

Review 2.  The genesis of tyrosine phosphorylation.

Authors:  Tony Hunter
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-05-01       Impact factor: 10.005

Review 3.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Authors:  S Shak
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 4.  Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

Authors:  P Sapra Sharma; R Sharma; T Tyagi
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications.

Authors:  James G Bilsland; Alan Wheeldon; Andrew Mead; Petr Znamenskiy; Sarah Almond; Kerry A Waters; Matthew Thakur; Vahri Beaumont; Timothy P Bonnert; Robert Heavens; Paul Whiting; George McAllister; Ignacio Munoz-Sanjuan
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

6.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

Review 7.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 8.  Receptor tyrosine kinases: legacy of the first two decades.

Authors:  Joseph Schlessinger
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-03-01       Impact factor: 10.005

9.  Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus.

Authors:  Na Li; Kazuhiro Nakamura; Yi Jiang; Hiromichi Tsurui; Shuji Matsuoka; Masaaki Abe; Mareki Ohtsuji; Hiroyuki Nishimura; Kiyoshi Kato; Takako Kawai; Tatsuya Atsumi; Takao Koike; Toshikazu Shirai; Hiroo Ueno; Sachiko Hirose
Journal:  Hum Mol Genet       Date:  2004-01-15       Impact factor: 6.150

10.  Leukocyte tyrosine kinase functions in pigment cell development.

Authors:  Susana S Lopes; Xueyan Yang; Jeanette Müller; Thomas J Carney; Anthony R McAdow; Gerd-Jörg Rauch; Arie S Jacoby; Laurence D Hurst; Mariana Delfino-Machín; Pascal Haffter; Robert Geisler; Stephen L Johnson; Andrew Ward; Robert N Kelsh
Journal:  PLoS Genet       Date:  2008-03-07       Impact factor: 5.917
View more
  4 in total

1.  Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

Authors:  Andrey V Reshetnyak; Jyotidarsini Mohanty; Francisco Tomé; David E Puleo; Alexander N Plotnikov; Mansoor Ahmed; Navjot Kaur; Anton Poliakov; Arul M Cinnaiyan; Irit Lax; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

Review 2.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

Review 3.  Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.

Authors:  Neha Sami; Vijay Kumar; Asimul Islam; Sher Ali; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Mol Neurobiol       Date:  2016-08-20       Impact factor: 5.590

Review 4.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.